Indivior Plc (Indivior) develops, manufactures, and sells buprenorphine-based prescription pharmaceuticals for the treatment of opioid dependence. The company operates through one reportable segment, the development, manufacture, and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company’s product portfolio includes buprenorphine-based Suboxone (buprenorphine and naloxone) tablet, Suboxone (buprenorphine and naloxone) sublingual film, Sublocade (buprenorphine extended-release) injection and Subutex (buprenorphine) tablet for the treatment of opioid dependence.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company conducts research to develop medications for the treatment of unmet needs, including diversion and abuse, and relapse. Indivior’s pipeline focuses on addressing substance use disorder, opioid disorder, and schizophrenia. In FY2023, the company incurred R&D expense of US$106 million, which as a percentage of total revenue, stood at 9.7% and has 108 employees working in the R&D division.